Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | BCHE | P06276 | 4/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15535898 | 0.87 | THRA (0.63) | THRATHRBBCHEALDH1A1LMNA | |
| SCHEMBL7166974 | 0.85 | MAPT (0.63) | THRBHRH3NPC1ALDH1A1LMNA | |
| SCHEMBL2472164 | 0.84 | TP53 (0.71) | THRATHRBBCHEACHE | |
| SCHEMBL434056 | 0.84 | L3MBTL1 (0.67) | THRATHRBBCHELMNAACHE | |
| SCHEMBL15537810 | 0.83 | THRA (0.59) | THRATHRBBCHELMNAACHE | |
| SCHEMBL15537107 | 0.82 | THRA (0.64) | THRATHRBBCHELMNARAB9A | |
| Hydrochloric Acid SCHEMBL3853408 | 0.82 | TP53 (0.69) | THRATHRBBCHEACHE | |
| SCHEMBL321662 | 0.82 | THRA (0.64) | THRATHRBBCHELMNAACHE | |
| Hydrochloric Acid SCHEMBL15049975 | 0.82 | TP53 (0.69) | THRATHRBBCHEACHE | |
| SCHEMBL2472562 | 0.81 | MAPT (0.66) | THRATHRBBCHEHRH3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238636-B2 | Process for preparation of dronedarone by Grignard reaction | SANOFI (FR) | 2016-01-19 | — | — | US | disclosed |
| US-20150274688-A1 | PROCESS FOR PREPARATION OF DRONEDARONE BY GRIGNARD REACTION | SANOFI (FR) | 2015-10-01 | — | — | US | disclosed |
| WO-2013178337-A1 | PROCESS FOR PREPARATION OF DRONEDARONE BY GRIGNARD REACTION | SANOFI (FR) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274688-A1 | PROCESS FOR PREPARATION OF DRONEDARONE BY GRIGNARD REACTION | CYP3A4, CYP2C9, CYP4B1 | THRA 4251/4885THRB 4438/4885BCHE 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.